Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study

[1]  Y. Ho,et al.  Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways. , 2011, Chemico-biological interactions.

[2]  P. Tchounwou,et al.  Basic Mechanisms of Arsenic Trioxide (ATO)-Induced Apoptosis in Human Leukemia (HL-60) Cells , 2010, Journal of hematology & oncology.

[3]  Mario Petrini,et al.  Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. , 2010, Cancer genetics and cytogenetics.

[4]  S. Galimberti,et al.  WT1 expression levels at diagnosis could predict long‐term time‐to‐progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes , 2010, British journal of haematology.

[5]  W. Hofmann,et al.  Molecular mechanisms involved in the progression of myelodysplastic syndrome. , 2010, Future oncology.

[6]  E. Thiel,et al.  A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.

[7]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[8]  Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. , 2008, Leukemia research.

[9]  A. Verma,et al.  Inhibition of p38α MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment , 2008, Leukemia & lymphoma.

[10]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Kenific,et al.  Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. , 2006, Cancer research.

[12]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[13]  H. Dombret,et al.  Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Hainsworth,et al.  Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Dörken,et al.  Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway , 2005, Oncogene.

[16]  B. Dörken,et al.  Inhibition of NF- (cid:1) B essentially contributes to arsenic-induced apoptosis , 2003 .

[17]  O. Sordet,et al.  Expression and activity of caspases 1 and 3 in myelodysplastic syndromes , 2000, Leukemia.

[18]  S. Rafii,et al.  Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. , 2000, Blood.

[19]  K. Bhalla,et al.  Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). , 2000, Blood.

[20]  R. Klein,et al.  Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases , 1999, Medical oncology.

[21]  P. Greenberg,et al.  Prognostic factors and scoring systems in myelodysplastic syndromes. , 1998, Haematologica.

[22]  G. Wong,et al.  Molecular cloning and expression of a receptor for human tumor necrosis factor , 1990, Cell.